Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinically relevant differences between the statins: implications for therapeutic selection.

P H Chong1, J D Seeger, C Franklin

  • 1Cook County Hospital, Chicago, Illinois 60612-3736, USA.

The American Journal of Medicine
|October 5, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Montelukast as a novel therapeutic approach in metastatic uveal melanoma harboring a CYSLTR2 mutation: a translational case report.

ESMO open·2025
Same author

Understanding context: leveraging the pragmatic robust implementation sustainability model to inform the implementation of a community-based southeastern preconception counseling intervention to improve maternal health equity.

Discover health systems·2025
Same author

The current evidence of solution-focused brief therapy: A meta-analysis of psychosocial outcomes and moderating factors.

Clinical psychology review·2024
Same author

Surgical management of superficial digital flexor tendon luxation in dogs: 48 cases (2005-2020).

The Journal of small animal practice·2021
Same author

U.S. prevalence of endocrine therapy-naïve locally advanced or metastatic breast cancer.

Current oncology (Toronto, Ont.)·2019
Same journal

Mineralocorticoid Antagonists for Post-MI HFpEF: Plausible Biology Meets Low Residual Risk?

The American journal of medicine·2026
Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026
Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026
Same journal

Cave Canem - Beware of the Dog.

The American journal of medicine·2026
Same journal

Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

The American journal of medicine·2026
Same journal

Mesenteric panniculitis.

The American journal of medicine·2026
See all related articles

Different statins offer varied benefits in lowering LDL cholesterol, with some showing greater efficacy, fewer drug interactions, and better cost-effectiveness. Understanding these differences aids in selecting the optimal statin medication for individual patient needs.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Development

Background:

  • Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are widely used for lipid lowering.
  • Significant variations exist among different statin medications.

Purpose of the Study:

  • To compare the clinical and economic differences among various statins.
  • To inform the selection of appropriate statin therapy.

Main Methods:

  • Comparative analysis of statin properties.
  • Evaluation of low-density lipoprotein (LDL) cholesterol-lowering efficacy.
  • Assessment of pharmacokinetic profiles and drug-food interactions.
  • Cost-effectiveness analysis based on LDL cholesterol reduction.

Related Experiment Videos

Main Results:

  • Atorvastatin and simvastatin demonstrate the highest LDL cholesterol-lowering efficacy.
  • Atorvastatin and fluvastatin exhibit minimal impact from renal function alterations.
  • Pravastatin and fluvastatin have fewer pharmacokinetic interactions due to not being metabolized by cytochrome P450 (3A4).
  • Fluvastatin, cerivastatin, and atorvastatin are the most cost-effective options per percentage change in LDL cholesterol.

Conclusions:

  • Key differences in efficacy, pharmacokinetics, and cost exist among statins.
  • Awareness of these variations is crucial for personalized statin selection and treatment adjustments.